Roberta Frapolli Selected Research

Myxoid Liposarcoma

1/2022	Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging.
1/2022	Corrigendum to "Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma" [Genomics Volume 113, Issue 5, September 2021, Pages 3439-3448].
1/2021	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
3/2020	Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
3/2020	Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
12/2019	Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
1/2019	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
11/2018	HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
2/2015	Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
10/2010	Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberta Frapolli Research Topics

Disease

40	Neoplasms (Cancer) 01/2022 - 09/2006
11	Myxoid Liposarcoma 01/2022 - 03/2010
9	Carcinoma (Carcinomatosis) 01/2016 - 09/2003
7	Ovarian Neoplasms (Ovarian Cancer) 09/2021 - 09/2006
5	Malignant Mesothelioma 11/2020 - 12/2016
4	Sarcoma (Soft Tissue Sarcoma) 11/2018 - 03/2010
3	Inflammation (Inflammations) 08/2020 - 02/2010
3	Liposarcoma 01/2019 - 03/2010
3	Mesothelioma 01/2017 - 01/2015
2	Disease Progression 01/2022 - 01/2019
2	Colonic Neoplasms (Colon Cancer) 08/2020 - 12/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 11/2006
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/2017 - 12/2016
2	Breast Neoplasms (Breast Cancer) 01/2017 - 12/2016
2	Adenocarcinoma 01/2015 - 08/2010
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2003 - 05/2002
1	Fibrosarcoma 11/2021
1	Cachexia 08/2020
1	Splenomegaly 08/2020
1	Colorectal Neoplasms (Colorectal Cancer) 12/2017
1	Metrorrhagia (Spotting) 03/2017
1	Triple Negative Breast Neoplasms 01/2017
1	Ewing Sarcoma (Sarcoma, Ewing) 03/2015
1	Glioblastoma (Glioblastoma Multiforme) 10/2013
1	Peripheral Nervous System Diseases (PNS Diseases) 08/2010
1	Multiple Myeloma 04/2010
1	Melanoma (Melanoma, Malignant) 11/2008

Drug/Important Bio-Agent (IBA)

20	TrabectedinIBA 01/2022 - 09/2003
11	Pharmaceutical PreparationsIBA 01/2022 - 02/2010
5	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 03/2010
5	Paclitaxel (Taxol)FDA LinkGeneric 09/2021 - 09/2006
4	PM 01183IBA 01/2022 - 11/2013
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2003
3	Pioglitazone (Actos)FDA Link 01/2022 - 12/2019
3	Imatinib Mesylate (Gleevec)FDA Link 11/2017 - 05/2002
3	Biological ProductsIBA 03/2017 - 10/2010
3	OTX015IBA 01/2017 - 12/2016
3	Irinotecan (Camptosar)FDA LinkGeneric 11/2008 - 10/2005
2	CytokinesIBA 08/2020 - 03/2010
2	Interleukin-6 (Interleukin 6)IBA 08/2020 - 03/2010
2	Tyrosine Kinase InhibitorsIBA 11/2017 - 10/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2010 - 11/2009
2	ST 1481 (Gimatecan)IBA 02/2010 - 10/2005
2	CamptothecinIBA 11/2006 - 10/2005
2	Topotecan (Hycamtin)FDA LinkGeneric 11/2006 - 10/2005
1	perforin-granzyme BIBA 11/2021
1	Immune Checkpoint InhibitorsIBA 11/2021
1	PEGPH20IBA 09/2021
1	AsbestosIBA 11/2020
1	Macrophage Colony-Stimulating FactorIBA 08/2020
1	LuciferasesIBA 08/2020
1	olaparibIBA 01/2020
1	niraparibIBA 01/2020
1	VimentinIBA 11/2018
1	RNA (Ribonucleic Acid)IBA 11/2018
1	Temozolomide (Temodar)FDA LinkGeneric 12/2017
1	PlatinumIBA 08/2017
1	Progesterone FDA LinkGeneric 01/2017
1	Estrogens (Estrogen)FDA Link 01/2017
1	Everolimus FDA Link 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	Gemcitabine FDA Link 01/2017
1	Therapeutic UsesIBA 12/2016
1	rho-Associated KinasesIBA 07/2016
1	Matrix Metalloproteinases (MMPs)IBA 07/2016
1	Staphylococcal Protein A (Protein A)IBA 03/2016
1	Chemotactic FactorsIBA 03/2016
1	Bevacizumab (Avastin)FDA Link 01/2016
1	Codon (Codons)IBA 10/2015
1	Tissue Inhibitor of Metalloproteinase-1IBA 02/2015
1	Tissue Inhibitor of Metalloproteinase-2IBA 02/2015
1	cathepsin SIBA 01/2015
1	Monoclonal AntibodiesIBA 01/2015
1	Peptide Hydrolases (Proteases)FDA Link 01/2015
1	Thrombospondin 1IBA 01/2015
1	PM 00104IBA 11/2013
1	Sunitinib (Sutent)FDA Link 10/2013
1	compound 0118IBA 10/2013
1	HMGA ProteinsIBA 03/2013
1	Propolis (Bee Bread)IBA 05/2012
1	Taxoids (Taxanes)IBA 08/2010
1	Erythropoietin FDA Link 08/2010
1	Docetaxel (Taxotere)FDA Link 08/2010
1	Neuroprotective AgentsIBA 08/2010
1	4- ((alpha- L- rhamnosyloxy)benzyl)isothiocyanateIBA 04/2010
1	NF-kappa B (NF-kB)IBA 04/2010
1	ChemokinesIBA 03/2010
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2009
1	vandetanib (ZD6474)IBA 11/2009
1	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 11/2009
1	ErbB Receptors (EGF Receptor)IBA 11/2009
1	LigandsIBA 11/2008

Therapy/Procedure

14	Therapeutics 01/2022 - 03/2010
3	Drug Therapy (Chemotherapy) 08/2010 - 09/2006
2	Immunotherapy 01/2022 - 11/2021
1	Aftercare (After-Treatment) 11/2021
1	Adjuvant Chemotherapy 11/2018
1	Oral Administration 05/2012
1	Biological Therapy 03/2010